ANL 31.47 Increased By ▲ 0.79 (2.57%)
ASC 14.10 Decreased By ▼ -0.84 (-5.62%)
ASL 23.80 Decreased By ▼ -0.10 (-0.42%)
AVN 94.75 Increased By ▲ 2.75 (2.99%)
BOP 9.14 No Change ▼ 0.00 (0%)
BYCO 9.78 Decreased By ▼ -0.47 (-4.59%)
DGKC 134.80 Decreased By ▼ -0.80 (-0.59%)
EPCL 52.25 Increased By ▲ 2.25 (4.5%)
FCCL 24.90 Increased By ▲ 0.28 (1.14%)
FFBL 24.80 Increased By ▲ 0.55 (2.27%)
FFL 15.20 Decreased By ▼ -0.40 (-2.56%)
HASCOL 10.75 Increased By ▲ 0.01 (0.09%)
HUBC 84.80 Decreased By ▼ -0.40 (-0.47%)
HUMNL 7.00 Decreased By ▼ -0.35 (-4.76%)
JSCL 24.94 Increased By ▲ 0.09 (0.36%)
KAPCO 37.40 Decreased By ▼ -0.45 (-1.19%)
KEL 4.08 Decreased By ▼ -0.07 (-1.69%)
LOTCHEM 14.45 Decreased By ▼ -0.33 (-2.23%)
MLCF 46.95 Increased By ▲ 0.35 (0.75%)
PAEL 37.19 Decreased By ▼ -1.06 (-2.77%)
PIBTL 11.68 Decreased By ▼ -0.12 (-1.02%)
POWER 10.22 Decreased By ▼ -0.28 (-2.67%)
PPL 90.65 Increased By ▲ 0.10 (0.11%)
PRL 25.30 Decreased By ▼ -0.80 (-3.07%)
PTC 8.75 Decreased By ▼ -0.20 (-2.23%)
SILK 1.41 Increased By ▲ 0.01 (0.71%)
SNGP 38.50 Increased By ▲ 0.40 (1.05%)
TRG 141.60 Increased By ▲ 0.50 (0.35%)
UNITY 29.75 Decreased By ▼ -1.75 (-5.56%)
WTL 1.54 Decreased By ▼ -0.03 (-1.91%)
BR100 4,912 Decreased By ▼ -23.77 (-0.48%)
BR30 25,332 Decreased By ▼ -71.47 (-0.28%)
KSE100 45,593 Decreased By ▼ -271.59 (-0.59%)
KSE30 19,056 Decreased By ▼ -117.19 (-0.61%)
World

China's Innovent Biologics plans $610mn share sale to expand production, clinical trials

  • The Jiangsu-based biopharmaceutical firm said TYVYT_ is co-developed in China by the company and US-based peer Eli Lilly.
15 Jan 2021

China's Innovent Biologics plans $610mn share sale to expand production, clinical trials

HONG KONG: China's biopharmaceutical group Innovent Biologics Inc said on Friday it planned to sell HK$4.727 billion ($609.70 million) stake in a share sale, raising funds for expansion of its production facilities and investment in clinical programmes.

The cancer drug developer said in a filing to the Hong Kong bourse that it plans to sell 52 million new shares, or 3.57% of the enlarged share capital, to third-party investors.

The new shares will be issued at HK$90.90 each, representing 4.87% discount to Thursday's close of HK$95.55 apiece.

Proceeds will also be used for building its second production facility in China's Suzhou for TYVYT_, to fund product licensing and possible M&A activities, and expand its production capacity.

Earlier in the week, Innovent said that China's National Medical Products Administration has accepted the supplemental New Drug Application for TYVYT_, or sintilimab injection, as second-line therapy for squamous non-small cell lung cancer.

The Jiangsu-based biopharmaceutical firm said TYVYT_ is co-developed in China by the company and US-based peer Eli Lilly.

Morgan Stanley & Co. International plc, Goldman Sachs (Asia) L.L.C. and J.P Morgan Securities (Asia Pacific) Ltd are the joint placing agents.